| Study | Clinical status | COVID-19 | Demographics | Environmental Exposure | Health Care | Imaging | Parent/ Caretaker | Quality of Life | Tests | Therapeutics |
|---|---|---|---|---|---|---|---|---|---|---|
| CSSCD | 1464 | 594 | 5 | 67 | 364 | 124 | 554 | 2482 | 503 | |
| walk-PHaSST | 302 | 29 | 15 | 71 | 33 | 228 | 360 | 269 | ||
| SAC | 350 | 8 | 32 | 11 | 22 | 1 | 103 | 166 | ||
| SIT Trial | 671 | 54 | 3 | 11 | 23 | 26 | 8 | 249 | 126 | |
| SCDIC-I Registry | 230 | 52 | 22 | 22 | 57 | 14 | 29 | 52 | ||
| HCT for SCD | 3 | 5 | 19 | 128 | ||||||
| SCCRIP | 81 | 46 | 95 | 419 | 18 | 175 | 168 | 197 | ||
| STOP I and II | 600 | 4 | 3 | 2 | 294 | 32 | 279 | 215 | ||
| MSH | 174 | 39 | 2 | 10 | 71 | 60 | 160 | 147 | ||
| (SC)2 | 170 | 25 | 68 | 21 | 109 | 37 | ||||
| SCDAA | 4 | 3 | 11 | 1 | 4 | 15 | ||||
| DISPLACE | 41 | 6 | 2 | 38 | 2 | 18 | 73 | |||
| OMG-SCD | 2 | 2 | 23 | 1 | ||||||
| PharmHU | 3 | 3 | 1 | |||||||
| REDS-BSCDC | 1 | 5 | 1 | |||||||
| PUSH_SCD | 16 | 5 | 5 | 2 | 38 | 3 | ||||
| Boston Brazil SCD | 6 | 1 | 8 | 1 | ||||||
| Baby HUG | 750 | 34 | 45 | 237 | 37 | 182 | 304 | 119 | ||
| BMT CTN - UD HCT for cSCD-0601 | 460 | 4 | 23 | 16 | 14 | 122 | 80 | 172 | ||
| CSCC-C-Data | 316 | 34 | 69 | 40 | 2 | 161 | 39 | 57 | ||
| SCDIC mESH | 3 | 18 | 172 | 20 | 83 | 73 | ||||
| SCDIC ALIGN | 13 | 5 | 114 | 20 | ||||||
| CSCC-Arginine | 62 | 4 | 19 | 34 | 1 | 313 | 29 | |||
| CSCC-Dexamethasone | 108 | 13 | 29 | 8 | 38 | 113 | 103 | |||
| CSCC-HU-Mg | 46 | 3 | 1 | 1 | 338 | 21 | ||||
| CSCC-Neuropsych | 510 | 15 | 13 | 28 | 111 | 45 | ||||
| CSCC-Priapism | 110 | 12 | 4 | 12 | 23 | 14 | ||||
| CIP | 2 | 2 | 1 | |||||||
| GE-SCD-iPS | 4 | 1 | ||||||||
| ASCQ-Me | 76 | 2 | 26 | 183 | 3 | |||||
| SCD NHDR | 155 | 5 | 23 | 21 | 87 | 48 | 107 | 92 |